WT1 and pancreatic ductal adenocarcinoma: Shigeo Koido et al. combined a novel WT1 peptide-pulsed dendritic cell (WT1-DC) vaccine with multiple chemotherapeutic drugs to treat unresectable advanced pancreatic ductal adenocarcinoma, causing significant infiltration of T cells and programmed cell death protein-1+ cells in the pancreatic tumor microenvironment (TME), making conversion surgery possible [85].